α-synuclein and the pathogenesis of Parkinson's disease

被引:25
|
作者
Martin, FL [1 ]
Williamson, SJM [1 ]
Paleologou, KE [1 ]
Allsop, D [1 ]
El-Agnaf, OMA [1 ]
机构
[1] Univ Lancaster, IENS, Dept Biol Sci, Lancaster LA1 4YQ, England
来源
PROTEIN AND PEPTIDE LETTERS | 2004年 / 11卷 / 03期
关键词
Parkinson's disease; DNA single-strand breaks; Fe(II); alpha-synuclein; Comet assay; comet tail length; reactive oxygen species; environmental causation;
D O I
10.2174/0929866043407138
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lesions known as Lewy bodies (LBs) and Lewy neurites (LNs) characterise brains of Parkinson's disease (PD) patients. Intracellular aggregation of alpha-synuclein (alpha-syn) appears to play a key role in the generation of LBs and LNs. Such aggregation in the presence of redox metals may initiate Fenton reaction-mediated generation of reactive oxygen species (ROS). ROS thus generated may result in cytotoxic mechanisms such as the induction of DNA single-strand breaks.
引用
收藏
页码:229 / 237
页数:9
相关论文
共 50 条
  • [31] α-synuclein degradation by autophagic pathways -: A potential key to Parkinson's disease pathogenesis
    Xilouri, Maria
    Vogiatzi, Tereza
    Vekrellis, Kostas
    Stefanis, Leonidas
    [J]. AUTOPHAGY, 2008, 4 (07) : 917 - 919
  • [32] Transcriptional mutagenesis of α-synuclein caused by DNA oxidation in Parkinson’s disease pathogenesis
    Sambuddha Basu
    Minkyung Song
    Levi Adams
    Inhye Jeong
    Goun Je
    Subhrangshu Guhathakurta
    Jennifer Jiang
    Nikpreet Boparai
    Wei Dai
    Fernando Cardozo-Pelaez
    Suren A. Tatulian
    Kyu Young Han
    Jordan Elliott
    Jean Baum
    Pamela J. McLean
    Dennis W. Dickson
    Yoon-Seong Kim
    [J]. Acta Neuropathologica, 2023, 146 : 685 - 705
  • [33] Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease
    Antonio Castillo-Gonzalez, Juan
    De Jesus Loera-Arias, Maria
    Saucedo-Cardenas, Odila
    Montes-de-Oca-Luna, Roberto
    Garcia-Garcia, Aracely
    Rodriguez-Rocha, Humberto
    [J]. PARKINSONS DISEASE, 2017, 2017
  • [34] α-synuclein fibrillogenesis is nucleation-dependent -: Implications for the pathogenesis of Parkinson's disease
    Wood, SJ
    Wypych, J
    Steavenson, S
    Louis, JC
    Citron, M
    Biere, AL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (28) : 19509 - 19512
  • [35] β-Synuclein Intermediates α-Synuclein Neurotoxicity in Parkinson's Disease
    Xian, Meiyan
    Li, Jingwen
    Liu, Tingting
    Hou, Kaiying
    Sun, Lin
    Wei, Jianshe
    [J]. ACS CHEMICAL NEUROSCIENCE, 2024, 15 (13): : 2445 - 2453
  • [36] Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson's disease in Drosophila
    Liu, Wei
    Lim, Kah-Leong
    Tan, Eng-King
    [J]. TRANSLATIONAL NEURODEGENERATION, 2022, 11 (01)
  • [37] Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila
    Wei Liu
    Kah-Leong Lim
    Eng-King Tan
    [J]. Translational Neurodegeneration, 11
  • [38] Transcriptional mutagenesis of a-synuclein caused by DNA oxidation in Parkinson's disease pathogenesis
    Basu, Sambuddha
    Song, Minkyung
    Adams, Levi
    Jeong, Inhye
    Je, Goun
    Guhathakurta, Subhrangshu
    Jiang, Jennifer
    Boparai, Nikpreet
    Dai, Wei
    Cardozo-Pelaez, Fernando
    Tatulian, Suren A.
    Han, Kyu Young
    Elliott, Jordan
    Baum, Jean
    Mclean, Pamela J.
    Dickson, Dennis W.
    Kim, Yoon-Seong
    [J]. ACTA NEUROPATHOLOGICA, 2023, 146 (05) : 685 - 705
  • [39] Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis
    Alberio, Tiziana
    Bossi, Alessandra Maria
    Milli, Alberto
    Parma, Elisa
    Gariboldi, Marzia Bruna
    Tosi, Giovanna
    Lopiano, Leonardo
    Fasano, Mauro
    [J]. FEBS JOURNAL, 2010, 277 (23) : 4909 - 4919
  • [40] An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics
    Javed, Hayate
    Kamal, Mohammad Amjad
    Ojha, Shreesh
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2016, 15 (10) : 1240 - 1252